Selinexor for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Sep 2020: Trial registered, NCT04562389
  2. 11 Mar 2021: Trial started, NCT04562389

The trials

NCT04562389: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

State
Under way
Phase
Phase 3
People
353 taking part
Started
11 Mar 2021
Primary completion
20 Feb 2026
Arms
Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID, Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID, Phase 1b: Selinexor and Ruxolitinib BID, Phase 3: Selinexor 60 mg + Ruxolitinib BID
Results
None posted
  1. 24 Sep 2020: Trial registered
  2. 11 Mar 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Xpovio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.